Baoji Pharma-B (02659.HK) is now open for subscription, introducing three cornerstone investors including Anke Biotechnology Hong Kong to subscribe to HK$200.6 million of shares.

According to the information obtained from the Securities Times APP, Baoji Pharmaceutical-B (02659.HK) will be listed from December 2 to December 5, 2025, with a plan to globally issue 37.9117 million shares, of which 10% will be allocated for sale in Hong Kong and 90% for international sale. The highest public offering price is HK$26.38 per share, with a minimum subscription of 100 shares and an entry fee of approximately HK$2,664. It is expected that the shares will start trading on the Hong Kong Stock Exchange on December 10, 2025.